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ORIGINAL RESEARCH
Association Between Frailty and Atrial 
Fibrillation in Older Adults: The Framingham 
Heart Study Offspring Cohort
Ariela R. Orkaby , MD, MPH; Jelena Kornej , MD, MSc; Steven A. Lubitz , MD, MPH;  
David D. McManus, MD, ScM; Thomas G. Travison, PhD; Jason A. Sherer, MD, MPH; Ludovic Trinquart , PhD; 
Joanne M. Murabito, MD, ScM; Emelia J. Benjamin , MD, ScM; Sarah R. Preis, ScD, MPH
BACKGROUND: Frailty is associated bidirectionally with cardiovascular disease. However, the relations between frailty and atrial 
fibrillation (AF) have not been fully elucidated.
METHODS AND RESULTS: Using the FHS (Framingham Heart Study) Offspring cohort, we sought to examine both the associa-
tion between frailty (2005–2008) and incident AF through 2016 and the association between prevalent AF and frailty status 
(2011–2014). Frailty was defined using the Fried phenotype. Models adjusted for age, sex, and smoking. Cox proportional 
hazards models, adjusted for competing risk of death, assessed the association between prevalent frailty and incident AF. 
Logistic regression models assessed the association between prevalent AF and new-onset frailty. For the incident AF analysis, 
we included 2053 participants (56% women; mean age, 69.7±6.9 years). By Fried criteria, 1018 (50%) were robust, 903 (44%) 
were prefrail, and 132 (6%) were frail. In total, 306 incident cases of AF occurred during an average 9.2 (SD, 3.1) follow-up 
years. After adjustment, there was no statistically significant association between prevalent frailty status and incident AF (pre-
frail versus robust: hazard ratio [HR], 1.22 [95% CI, 0.95–1.55]; frail versus robust: HR, 0.92 [95% CI, 0.57–1.47]). At follow-up, 
there were 111 new cases of frailty. After adjustment, there was no statistically significant association between prevalent AF 
and new-onset frailty (odds ratio, 0.48 [95% CI, 0.17–1.36]).
CONCLUSIONS: Although a bidirectional association between frailty and cardiovascular disease has been suggested, we did 
not find evidence of an association between frailty and AF. Our findings may be limited by sample size and should be further 
explored in other populations.
Key Words: association study ■ atrial fibrillation ■ frailty
As the population successfully ages, the incidence of atrial fibrillation (AF) will continue to increase.1 Frailty, a common geriatric syndrome that is as-
sociated with increased risk of morbidity and mortality,2 
is associated with both subclinical and overt cardio-
vascular disease (CVD).3,4 To date, the only proven 
approach for frailty prevention involves physical ac-
tivity,2 which is also a component of AF prevention.5,6 
However, the relations between frailty and AF have are 
not fully understood and may present an important op-
portunity for prevention of both AF and frailty.
Many factors have been associated with an in-
creased risk of frailty, including age, low physical ac-
tivity, smoking, metabolic syndrome, and CVD, all of 
which are also risk factors for AF.5,7-10 A survey sent 
to 41 centers that participate in the European Heart 
Rhythm Association Electrophysiology Research 
Network reported that the prevalence of AF in frail 
patients was 72%, more common than heart failure 
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(69%), diabetes mellitus (36%), or coronary artery dis-
ease (31%).11 In a cohort of 132 older adults (mean age, 
73 years) who were hospitalized with AF in Poland, 
frailty was diagnosed in 60%.12
We hypothesized that AF and frailty are reciprocally 
related. We sought to examine whether (1) frailty is as-
sociated with increased risk of incident AF and (2) AF 
is associated with increased risk of new-onset frailty.
METHODS
The FHS (Framingham Heart Study) data used in this 
publication are available at dbGaP, BioLINCC, and 
the FHS data service center (https://frami ngham heart 
study.org/fhs-for-resea rcher s/data-avail able-overv 
iew/).
Study Sample
The present study was based on the FHS Offspring 
cohort.13,14 FHS procedures have been described 
previously.14-16 Briefly, the FHS Original cohort began 
in 1948 with the enrollment of 5209 study partici-
pants residing in the community of Framingham, 
MA. In 1971, the children of the Original cohort par-
ticipants and their spouses were enrolled into the 
FHS Offspring cohort. Offspring participants were 
invited to an in-person study examination every 4 
to 8 years.13,14 The Offspring examinations included 
detailed information obtained by trained study per-
sonnel on medical history, laboratory measures, and 
assessments of cognitive and physical function. All 
study participants provided informed consent to par-
ticipate in this study. All protocols were approved by 
the Institutional Review Board at Boston University 
Medical Center (Boston, MA).
Our study sample was derived from the 3021 
participants who attended Offspring cohort exam-
ination cycle 8 (2005–2008), the index examination. 
Participants were excluded if they were aged <60 years 
at the time of their study visit (n=693), had missing or 
incomplete Fried frailty scores (defined as missing ≥2 
components of the Fried score; n=63), or were missing 
covariate information for smoking status (n=3).
The present analysis is based on 2 different ana-
lytic samples. For the first analysis of the association 
between the Fried frailty status and incident AF, we ex-
cluded participants who had prevalent AF at the time of 
their index examination (n=205) or had no AF follow-up 
information (n=4), resulting in a final sample size of 2053. 
For the second analysis of the association between 
prevalent AF at the index examination and new-onset 
frailty at the follow-up examination, we excluded partic-
ipants who did not attend examination 9 (n=572), had a 
missing or incomplete Fried frailty score at examination 
9 (n=72), or had prevalent frailty at the index examination 
(n=52). In a secondary analysis, we reconstructed the 
samples using the Rockwood frailty definition, as pre-
viously defined in a prior Framingham study.17 Details of 
the study sample selection are shown in Figure 1.
Frailty
In FHS, frailty was defined according to 2 leading def-
initions: the phenotypic characterization developed 
by Fried and colleagues in the CHS (Cardiovascular 
Health Study)8 and the deficit accumulation model 
demonstrated by Rockwood and associates in the 
Yale Precipitating Events Project and elsewhere.17-19 
Our primary analysis was done using a modified Fried 
method, and a secondary analysis was done apply-
ing the Rockwood frailty definition. Briefly, the Fried 
method is based on a physical phenotype of frailty 
that includes 5 measures of function.8 Individuals 
are frail if they have at least 3 of the following: unin-
tentional weight loss of ≥10 pounds in the past year, 
self-reported exhaustion, weakness (as measured by 
grip strength), slow walking speed, and decreased 
physical activity. Those with 1 to 2 deficits are prefrail, 
whereas those with 0 deficits are nonfrail. Participants 
CLINICAL PERSPECTIVE
What Is New?
• The relationship between cardiovascular dis-
ease and frailty is thought to be bidirectional.
• Atrial fibrillation (AF) and frailty are associated 
in cross-sectional studies, but whether AF 
and frailty share a bidirectional relationship is 
unclear.
• In this study of 2053 participants in the FHS 
(Framingham Heart Study), we did not find a 
statistically meaningful relationship between AF 
and frailty.
What Are the Clinical Implications?
• It is possible that the development of AF may 
have differing mechanisms than atherosclerotic 
cardiovascular disease, which is closely associ-
ated with development of frailty.
• Further work is needed to understand the rela-
tionship between AF and frailty.
Nonstandard Abbreviations and Acronyms
ARIC Atherosclerosis Risk in Communities
CHS Cardiovascular Health Study
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who were unable to complete the walk test and/or 
grip strength test because of a noted physical limita-
tion were classified as having a deficiency.
In a secondary analysis, we defined frailty accord-
ing to the cumulative deficit method developed by 
Rockwood, using 37 variables related to cognition, 
physical function, mood, and morbidity, as we have 
previously defined in the FHS.17 Frailty indexes were 
calculated for each participant by dividing the num-
ber of accumulated deficits by the total number of 
possible deficits.20 A score of 0 to 0.1 was consid-
ered robust, a score of >0.1 to 0.21 was considered 
as prefrail, and a score of >0.21 was considered as 
frail.21
Figure 1. Study sample selection.
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AF and Coronary Heart Disease 
Assessment
All cardiovascular events were adjudicated by a 
panel of 3 FHS physicians based on a review of med-
ical records, ECGs, and physician/hospital reports, 
as previously described.22 Ongoing surveillance for 
CVD events is achieved through mailed medical his-
tory questionnaires and/or telephone interviews in 
between the official study visits. AF was considered 
present if either AF or atrial flutter was diagnosed on 
ECG or Holter monitoring at an FHS research visit, 
during examination by an outside clinician, or on in-
patient admission to hospital.23 Coronary heart dis-
ease was defined as the occurrence of myocardial 
infarction, angina, coronary insufficiency, or coronary 
heart disease–associated death. Diagnosis of con-
gestive heart failure was performed using standard-
ized criteria.24
Covariates
All covariates were measured at the index examina-
tion to characterize participant phenotypes relevant 
to downstream risks. Height and weight were as-
sessed using a standardized protocol. If a partici-
pant was missing height, we carried forward his/her 
height measurements from prior FHS examinations, 
if available. Smoking was classified as present if the 
participant reported smoking cigarettes in the year 
before the index examination. Systolic and diastolic 
blood pressure values were taken as the average of 
2 physician readings using a sphygmomanometer. 
Antihypertensive and diabetes mellitus medications 
were assessed as part of a systematic drug inventory. 
Diabetes mellitus was defined as fasting blood glu-
cose ≥126 mg/dL or use of oral hypoglycemic medica-
tions or insulin, as indicated on medication inventory. 
A clinically significant murmur was defined as having 
a systolic murmur of grade ≥3 of 6 or any diastolic 
murmur, as assessed by the research center physi-
cian. PR interval and left ventricular hypertrophy were 
obtained from ECG obtained in the research center.
Statistical Analysis
Descriptive statistics were calculated using means 
and SDs for continuous variables and frequency 
counts and percentages for categorical variables. 
For the analysis of prevalent frailty at the index exam-
ination and incident AF, participants were followed 
up from the date of their index examination until AF 
occurrence, death, loss to follow-up, or December 
31, 2016, whichever occurred first. Cox proportional 
hazards models were used to estimate hazard ratios 
(HRs) and compute associated 95% CIs, quantifying 
the association between frailty group (prefrail versus 
robust or frail versus robust) and incident AF. The 
proportional hazards assumption was verified by in-
cluding a term for the interaction between the log of 
the survival time and each predictor in the model. An 
initial model (model 1) was adjusted for age and sex, 
and a second model (model 2) was further adjusted 
for current smoking. We additionally constructed 
a third model that was further adjusted for height, 
weight, systolic and diastolic blood pressure, antihy-
pertensive treatment, diabetes mellitus, PR interval, 
left ventricular hypertrophy, murmur, prevalent coro-
nary heart disease, and prevalent heart failure. For all 
models, the Fine-Gray model was used to account 
for the competing risk of mortality.25
Unlike cardiovascular events, which are continu-
ously monitored in between study visits, frailty status is 
only assessed during a participant’s study visit so it is 
not possible to obtain the survival time for frailty onset. 
Thus, logistic regression models were used for the 
analysis of prevalent AF at the index examination, and 
new-onset frailty (frail versus prefrail/robust) was as-
sessed at the follow-up examination (FHS examination 
cycle 9 [2011–2014]). Multivariable models were ad-
justed for the same covariates used in the incident AF 
analysis, described above. Frailty group was defined 
using the Fried frailty criteria in our primary analysis, 
and the Rockwood Index was used in our secondary 
analysis. All analyses were performed using SAS ver-
sion 9.4 (SAS Institute, Cary, NC). A 2-sided P<0.05 
was considered statistically significant.
RESULTS
For our analysis of the association between the Fried frailty 
score and incident AF, our study sample included 2053 
participants (56% women; mean age, 69.7±6.9 years). A 
total of 306 incident cases of AF occurred during an av-
erage of 9.2±3.1 years of follow-up. Details of the study 
sample selection are shown in Figure 1.
Table  1 shows a summary of the study sample 
characteristics by Fried frailty category. Overall, frail 
participants were older, were heavier, had slower 
walking speeds, and were more likely to be current 
smokers, have diabetes mellitus, use hypertensive 
treatment, and have prevalent coronary heart dis-
ease and heart failure, compared with participants 
who were robust or prefrail. Table 2 shows a sum-
mary of the study sample characteristics stratified by 
the presence of AF at the time of the index examina-
tion. Participants with AF were older, were more likely 
to be men, and were more likely to have a higher bur-
den of CVD risk factors as opposed to participants 
without AF. Summary statistics for the secondary 
analysis using the Rockwood frailty index are pre-
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Among the 2328 participants aged ≥60 years at 
the index examination, ≈3% (n=63) were missing the 
Fried frailty score (defined as missing ≥2 of 5 pos-
sible components) and ≈5% (n=112) were missing 
the Rockwood frailty index (defined as missing ≥5 
of 37 possible components). Compared with partic-
ipants with complete Fried frailty scores, those with 
missing scores were older (80.0 versus 70.1  years; 
P<0.0001), had lower diastolic blood pressure (69 
versus 72  mm  Hg; P=0.01), were more likely to be 
women (70% versus 55%; P=0.02), and had a higher 
prevalence of hypertension treatment (71% versus 
55%; P=0.01), coronary heart disease (25% versus 
13%; P=0.004), congestive heart failure (11% versus 
3%; P=0.004), and AF (18% versus 9%; P=0.02) at 
the index examination (Table  S3). Participants with 
missing Fried frailty scores were more likely to de-
velop incident AF (27% versus 15%) or to die (62% 
versus 19%) during the follow-up period (P<0.0001). 
Mean systolic blood pressure and percentage of cur-
rent smokers were similar between those with and 
without missing Fried frailty status (Table S3).
Association Between Frailty Status at 
Index Examination and Incident AF
Using the Fried criteria, 1018 (50%) participants were 
robust, 903 (44%) were prefrail, and 132 (6%) were 
frail at the index examination. After adjustment for age, 
sex, and smoking, and accounting for the competing 
risk of mortality, we found no statistically significant 
association between index frailty status and incident 
AF (pre-frail versus robust: HR, 1.22 [95% CI, 0.95–
1.55] [P=0.11]; frail versus robust: HR, 0.92 [95% CI, 
0.57–1.47] [P=0.72]), with similar results after full model 
adjustment (Table 3). In secondary analysis using the 
Rockwood frailty definition, there was a suggestion of 
a positive association between frailty status and inci-
dent AF (prefrail versus robust: HR, 1.32 [95% CI, 1.01–
1.72] [P=0.04]; frail versus robust: HR, 1.32 [95% CI, 
0.96–1.83] [P=0.09]). However, the results were attenu-
ated in the fully adjusted model and were comparable 
to the results using the Fried criteria (Table 3). Model 
results unadjusted for the competing risk of mortality 
are presented in Table S4.
Association Between Prevalent AF and 
New-Onset Frailty
In the analysis of new-onset frailty at the follow-up 
examination, 86 (5.5%) participants had AF at the 
index examination. There was a total of 111 new-
onset cases of frailty at the follow-up examination 
(mean time between index and follow-up examina-
tion, 5.8±0.6  years). After adjustment for age, sex, 
and smoking, there was no statistically significant 
association between prevalent AF and incident frailty 
(odds ratio [OR], 0.48 [95% CI, 0.17–1.36] [P=0.17]). 
When using the Rockwood frailty definition, the 
OR was 1.47 (95% CI, 0.79–2.73; P=0.22). Results 
Table 1. Study Sample Characteristics of the FHS Offspring Cohort Participants Included in the Analysis of Fried Frailty 
Group at Examination 8 and Incident AF (N=2053)
Characteristic All Participants (n=2053)
Fried Frailty Group
Robust (n=1018) Prefrail (n=903) Frail (n=132)
Age, mean (SD), y 69.7 (6.9) 67.9 (6.1) 70.8 (7.0) 75.7 (7.3)
Women, n (%) 1153 (56.2) 535 (52.6) 540 (59.8) 78 (59.1)
Current smoker, n (%) 155 (7.6) 65 (6.4) 73 (8.1) 17 (12.9)
Diabetes mellitus, n (%) 299 (14.9) 117 (11.6) 150 (17.1) 32 (27.1)
Height, mean (SD), in 65.3 (3.8) 65.9 (3.8) 64.9 (3.7) 64.1 (3.7)
Weight, mean (SD), lb 171 (38) 169 (37) 174 (38) 172 (46)
Systolic blood pressure, mean (SD), mm Hg 131 (17) 130 (17) 131 (17) 132 (19)
Diastolic blood pressure, mean (SD), mm Hg 73 (10) 74 (10) 72 (10) 68 (10)
Antihypertensive treatment, n (%) 1104 (53.9) 498 (49.0) 519 (57.6) 87 (65.9)
PR interval, mean (SD), ms 17.0 (2.9) 16.9 (2.7) 17.0 (3.0) 17.5 (3.2)
Heart murmur, n (%) 63 (3.2) 25 (2.6) 32 (3.7) 6 (5.2)
Left ventricular hypertrophy, n (%) 15 (0.75) 5 (0.50) 9 (1.0) 1 (0.82)
Prevalent heart failure, n (%) 25 (1.2) 6 (0.59) 14 (1.6) 4 (3.8)
Prevalent coronary heart disease, n (%) 212 (10.3) 80 (7.9) 108 (12.0) 24 (18.2)
Fried frailty score, mean (SD) 0.78 (0.97) 0 (0.0) 1.28 (0.45) 3.32 (0.51)
Rockwood Frailty Index score, mean (SD) 0.14 (0.11) 0.093 (0.065) 0.17 (0.098) 0.35 (0.13)
Usual walking speed, mean (SD), m/s 1.17 (0.27) 1.29 (0.21) 1.09 (0.25) 0.78 (0.20)
Participants with prevalent AF at examination 8 (n=205) were excluded. Characteristics were measured at examination 8. AF indicates atrial fibrillation; and 
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were similar in the fully adjusted multivariable model 
(Table 4).
DISCUSSION
In this prospective cohort study, we did not find evi-
dence of a statistically significant association between 
frailty and incident AF or AF and new-onset frailty, 
defined according to the 2 leading frailty definitions, 
once the intervening influences of age, sex, and cur-
rent smoking status were considered (Figure 2). Data 
on the association between AF and frailty have been 
conflicting to date and largely have focused on preva-
lent conditions.
CVD and frailty are thought to share a bidirectional 
relationship3; however, our findings do not support 
this relationship for AF and frailty. The development 
of AF may have differing mechanisms than athero-
sclerotic CVD, which is closely associated with de-
velopment of frailty. Normal physiologic aging of the 
Table 2. Study Sample Characteristics of the FHS 
Offspring Cohort Participants Included in the Analysis of 
Prevalent AF at Examination 8 and New-Onset Frailty, as 










Age, mean (SD), y 68.3 (6.2) 68.2 (6.1) 71.0 (6.4)
Women, n (%) 861 (55.0) 831 (56.2) 30 (34.9)
Current smoker, n (%) 105 (6.7) 101 (6.8) 4 (4.7)
Diabetes mellitus, n (%) 204 (13.2) 187 (12.8) 17 (20.2)
Height, mean (SD), in 65.6 (3.8) 65.5 (3.8) 67.0 (4.0)
Weight, mean (SD), lb 173 (38) 172 (37) 190 (41)
Systolic blood pressure, 
mean (SD), mm Hg
130 (17) 130 (17) 127 (18)
Diastolic blood pressure, 
mean (SD), mm Hg
73 (10) 73 (10) 72 (9)
Antihypertensive treatment, 
n (%)
806 (51.5) 750 (50.7) 56 (65.1)
PR interval, mean (SD), ms 16.9 (2.8) 16.8 (2.7) 18.2 (3.3)
Heart murmur, n (%) 47 (3.1) 44 (3.1) 3 (3.6)
Left ventricular hypertrophy, 
n (%)
9 (0.59) 8 (0.55) 1 (1.27)
Prevalent heart failure, n (%) 20 (1.3) 10 (0.68) 10 (11.6)
Prevalent coronary heart 
disease, n (%)
157 (10.0) 129 (8.7) 28 (32.6)
Fried frailty score, mean (SD) 0.55 (0.69) 0.54 (0.68) 0.70 (0.75)
Rockwood Frailty Index 
score, mean (SD)




Usual walking speed, mean 
(SD), m/s
1.22 (0.25) 1.22 (0.25) 1.13 (0.26)
Participants with prevalent frailty using Fried criteria at examination 8 
(n=52) were excluded. Characteristics were measured at examination 8. AF 
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cardiovascular system includes adverse cardiac struc-
tural and electrophysiological remodeling with age, 
which predisposes to arrhythmias, most commonly 
AF.26 Aging-related changes in the electrical conduc-
tion system of the heart may not directly impact other 
organ systems. This contrasts with other physiologic 
changes throughout the cardiovascular system, which 
are related to the development of frailty. For exam-
ple, the natural increase of collagen cross-linking and 
reduction in elastin fibers with age lead to increased 
risk of arterial stiffness and higher afterload and sys-
tolic pressure.27 Similarly, endothelial response to 
endogenous nitrous oxide declines over the lifespan, 
which increases the risk of coronary artery disease 
and peripheral vascular disease.28 Neither of these 
physiologic changes is limited to the heart and may 
be implicated in the bidirectional relationship between 
CVD and frailty. On the other hand, AF may represent 




Fried (N=1566) Rockwood (N=1343)
No. of Frail/Total No. 
of Participants OR (95% CI) P Value
No. of Frail/Total No. 
of Participants OR (95% CI) P Value
Age/sex 111/1566 0.48 (0.17–1.36) 0.17 238/1343 1.47 (0.79–2.72) 0.22
Age/sex/smoking 111/1566 0.48 (0.17–1.36) 0.17 238/1343 1.47 (0.79–2.73) 0.22
Multivariable* 101/1447 0.50 (0.12–2.18) 0.36 218/1253 2.01 (0.90–4.51) 0.09
The outcome is frail vs prefrail/robust (referent). Participants with prevalent frailty at examination 8 are excluded (n=52 for Fried criteria, and n=241 for 
Rockwood criteria). AF indicates atrial fibrillation; and OR, odds ratio.
*Models are adjusted for age, sex, current smoking, height, weight, systolic and diastolic blood pressure, antihypertensive treatment, diabetes mellitus, PR 
interval, left ventricular hypertrophy, heart murmur, prevalent coronary heart disease, and prevalent heart failure.
Figure 2. Study summary.
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a physiologic change of aging that on its own is not 
associated with an increased risk of frailty, similar to 
the development of cataracts, which occur as part of 
the normal aging process in most people.19
Data from the ARIC (Atherosclerosis Risk in 
Communities) Study reported a higher prevalence of 
AF among those who were frail (17% versus 7%),29 as 
did data from the CHS (4.3% versus 1.5%).4 The CHS 
further examined the cross-sectional association be-
tween frailty and prevalent AF and found no statisti-
cally significant increase in the odds of AF in those who 
were frail versus nonfrail (OR, 1.90; 95% CI, 0.82–4.39; 
P=0.33), similar to our study.4 A systematic review 
conducted in 2017 identified 10 observational cohort 
studies that explored the relationship between AF and 
frailty, defined in multiple ways.30 Results were incon-
clusive, with an overall suggestion that among those 
with frailty, AF was common (48%–75%), whereas 
for those with AF, frailty may be common (4%–75%). 
Although one included study was longitudinal in design 
for anticoagulation outcomes,31 none examined the re-
lationship between frailty and incident AF or AF and 
incident frailty.
To our knowledge, most studies have instead ex-
amined the relationship between poor outcomes and 
lower use of anticoagulation in those who are frail with 
AF.32,33 These are important clinical questions to im-
prove the management of older, frail patients; however, 
they do not address the underlying questions about 
whether AF and frailty are related.34 Further work is 
needed to understand the interplay between these 2 
conditions.
Our study has important limitations. We examined 
an observational, cohort study; and although we have 
accounted for many confounders, we cannot exclude 
residual confounding or establish causal relations. 
Only those who could complete the frailty assessment 
for the Fried definition could be included. Participants 
with missing frailty scores had more adverse risk fac-
tor profiles and a higher occurrence of both AF and 
death, which may have biased the results. The number 
of events was low, and we may have failed to detect 
true associations of smaller magnitude between AF 
and frailty. Results may be not be applicable to other 
ages and races/ethnicities not represented in the FHS.
This study also has several strengths. FHS has de-
tailed and routinely ascertained covariates, including 
adjudicated events, such as AF. Using longitudinal data, 
we were able to examine the bidirectional relationship 
between the development of AF and frailty. We were able 
to define frailty according to the 2 leading definitions.
In conclusion, although a bidirectional associa-
tion between frailty and CVD has been suggested 
in other studies, we did not find evidence of a rela-
tionship between frailty and AF. Our findings may be 
limited by sample size and should be confirmed in 
other populations. In addition, further exploration of 
potential bias attributable to missing frailty status is 
warranted.
ARTICLE INFORMATION
Received July 15, 2020; accepted November 24, 2020.
Affiliations
From the New England GRECC (Geriatric Research, Education, and Clinical 
Center), VA Boston Healthcare System, Boston, MA (A.R.O.); Division of 
Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 
(A.R.O.); National Heart, Lung, and Blood Institute’s FHS (Framingham Heart 
Study), Framingham, MA (J.K., E.J.B.); Sections of Cardiovascular Medicine 
and Preventive Medicine, Boston Medical Center, Boston University School 
of Medicine, Boston, MA (J.K., E.J.B.); Cardiology Division, Massachusetts 
General Hospital, Harvard Medical School, Boston, MA (S.A.L.); Department 
of Medicine, University of Massachusetts Medical School, Worcester, MA 
(D.D.M.); Marcus Institute for Aging Research, Hebrew Senior Life, Harvard 
Medical School, Boston, MA (T.G.T.); Section of General Internal Medicine, 
Department of Medicine, Boston University School of Medicine, Boston, MA 
(J.A.S., J.M.M.); Department of Biostatistics (L.T., S.R.P.), and Department 
of Epidemiology (E.J.B.), Boston University School of Public Health, Boston, 
MA; and Section of Cardiovascular Medicine, Department of Medicine, 
Boston University School of Medicine, Boston, MA (E.J.B.).
Acknowledgments
We are grateful to the FHS (Framingham Heart Study) participants for allow-
ing us to conduct this research.
Sources of Funding
This work was supported by FHS (Framingham Heart Study) grant 
75N92019D00031. Dr Orkaby is supported by VA CSR&D CDA-2 Award 
IK2-CX001800 and National Institute on Aging (NIA) R03-AG060169. Dr 
Benjamin is supported by National Heart, Lung, and Blood Institute (NHLBI) 
R01HL128914, 2R01 HL092577, 1R01 HL141434 01A1, and 2U54HL120163; 
NIA 1R01AG066010; and American Heart Association 18SFRN34110082. Dr 
Trinquart is supported by the American Heart Association 18SFRN34150007. 
Dr Kornej is supported by the European Union’s Horizon 2020 Research 
and Innovation Programme under the Marie Sklodowska-Curie Actions 
grant agreement No. 838259. Dr Travison is supported by the Boston Older 
Americans Independence Center biostatistical design and analysis core 
AG031679-6778. Dr Lubitz is supported by National Institutes of Health 
grant 1R01HL139731; and American Heart Association 18SFRN34250007. 
Dr McManus is supported by R01HL126911, R01HL137734, R01HL137794, 
R01HL135219, R01HL136660, U54HL143541, and 1U01HL146382 from the 
NHLBI.
Disclosures
Dr Lubitz receives sponsored research support from Bristol Myers Squibb/
Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit; has consulted for Bristol 
Myers Squibb/Pfizer and Bayer AG; and participates in a research collabora-




 1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, 
Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 Year trends 
in atrial fibrillation prevalence, incidence, risk factors, and mortality in 
the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–
162. DOI: 10.1016/S0140 -6736(14)61774 -8.
 2. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly peo-
ple. Lancet. 2013;381:752–762. DOI: 10.1016/S0140 -6736(12)62167 -9.
 3. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, 
Popma JJ, Ferrucci L, Forman DE. Frailty assessment in the cardio-





 http://ahajournals.org by on February 16, 2021
J Am Heart Assoc. 2021;10:e018557. DOI: 10.1161/JAHA.120.018557 9
Orkaby et al Atrial Fibrillation and Frailty
 4. Newman AB, Gottdiener JS, McBurnie MA, Hirsch CH, Kop WJ, Tracy 
R, Walston JD, Fried LP. Associations of subclinical cardiovascular dis-
ease with frailty. J Gerontol A Biol Sci Med Sci. 2001;56:M158–M166. 
DOI: 10.1093/geron a/56.3.M158.
 5. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey 
D, Alasady M, Hanley L, Antic NA, McEvoy RD, et al. Aggressive risk 
factor reduction study for atrial fibrillation and implications for the out-
come of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 
2014;64:2222–2231.
 6. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan 
R, Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, et al. Impact 
of CARDIOrespiratory FITness on arrhythmia recurrence in obese indi-
viduals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 
2015;66:985–996.
 7. Rienstra M, Lyass A, Murabito JM, Magnani JW, Lubitz SA, Massaro 
JM, Ellinor PT, Benjamin EJ. Reciprocal relations between physical dis-
ability, subjective health, and atrial fibrillation: the Framingham Heart 
Study. Am Heart J. 2013;166:171–178. DOI: 10.1016/j.ahj.2013.02.025.
 8. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener 
J, Seeman T, Tracy R, Kop WJ, Burke G, et al. Frailty in older 
adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 
2001;56:M146–M156. DOI: 10.1093/geron a/56.3.M146.
 9. Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, 
Vellas B. The i.A.N.A Task Force on frailty assessment of older people 
in clinical practice. J Nutr Health Aging. 2008;12:29–37. DOI: 10.1007/
BF029 82161.
 10. Perez-Tasigchana RF, Leon-Munoz LM, Lopez-Garcia E, Gutierrez-
Fisac JL, Laclaustra M, Rodriguez-Artalejo F, Guallar-Castillon P. 
Metabolic syndrome and insulin resistance are associated with frailty in 
older adults: a prospective cohort study. Age Ageing. 2017;46:807–812. 
DOI: 10.1093/agein g/afx023.
 11. Fumagalli S, Potpara TS, Bjerregaard Larsen T, Haugaa KH, Dobreanu 
D, Proclemer A, Dagres N. Frailty syndrome: an emerging clinical 
problem in the everyday management of clinical arrhythmias: the re-
sults of the European Heart Rhythm Association survey. Europace. 
2017;19:1896–1902. DOI: 10.1093/europ ace/eux288.
 12. Mlynarska A, Mlynarski R, Golba KS. Older age and a higher EHRA 
score allow higher levels of frailty syndrome to be predicted in patients 
with atrial fibrillation. Aging Male. 2017;20:23–27. DOI: 10.1080/13685 
538.2016.1241761.
 13. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The 
Framingham offspring study: design and preliminary data. Prev Med. 
1975;4:518–525. DOI: 10.1016/0091-7435(75)90037 -7.
 14. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An 
investigation of coronary heart disease in families: the Framingham off-
spring study. Am J Epidemiol. 1979;110:281–290. DOI: 10.1093/oxfor 
djour nals.aje.a112813.
 15. Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O’Connor GT, Rapoport 
DM, Redline S, Robbins J, Samet JM, et al. The Sleep Heart Health 
Study: design, rationale, and methods. Sleep. 1997;20:1077–1085.
 16. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches 
to heart disease: the Framingham Study. Am J Public Health Nations 
Health. 1951;41:279–281. DOI: 10.2105/AJPH.41.3.279.
 17. Orkaby AR, Lunetta KL, Sun FJ, Driver JA, Benjamin EJ, Hamburg 
NM, Mitchell GF, Vasan RS, Murabito JM. Cross-sectional association 
of frailty and arterial stiffness in community-dwelling older adults: the 
Framingham Heart Study. J Gerontol A Biol Sci Med Sci. 2019;74:373–
379. DOI: 10.1093/geron a/gly134.
 18. Liu CK, Lyass A, Larson MG, Massaro JM, Wang N, D’Agostino RB 
Sr, Benjamin EJ, Murabito JM. Biomarkers of oxidative stress are as-
sociated with frailty: the Framingham Offspring Study. Age (Dordr). 
2016;38:1. DOI: 10.1007/s1135 7-015-9864-z.
 19. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A stan-
dard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. DOI: 
10.1186/1471-2318-8-24.
 20. Mitnitski A, Song X, Skoog I, Broe GA, Cox JL, Grunfeld E, Rockwood 
K. Relative fitness and frailty of elderly men and women in developed 
countries and their relationship with mortality. J Am Geriatr Soc. 
2005;53:2184–2189. DOI: 10.1111/j.1532-5415.2005.00506.x.
 21. Pajewski NM, Williamson JD, Applegate WB, Berlowitz DR, Bolin LP, 
Chertow GM, Krousel-Wood MA, Lopez-Barrera N, Powell JR, Roumie 
CL, et al. Characterizing frailty status in the systolic blood pressure in-
tervention trial. J Gerontol A Biol Sci Med Sci. 2016;71:649–655. DOI: 
10.1093/geron a/glv228.
 22. Abbott RD, McGee DL. The Framingham Study: An Epidemiological 
Investigation of Cardiovascular Disease, Section 37: The Probability of 
Developing Certain Cardiovascular Diseases in Eight Years at Specified 
Values of Some Characteristics. Bethesda, MD: National Heart, Lung, 
and Blood Institute; 1987.
 23. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino 
RB, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, et al. 
Development of a risk score for atrial fibrillation (Framingham Heart 
Study): a community-based cohort study. Lancet. 2009;373:739–745. 
DOI: 10.1016/S0140 -6736(09)60443 -8.
 24. Mahmood SS, Wang TJ. The epidemiology of congestive heart fail-
ure: the Framingham Heart Study perspective. Glob Heart. 2013;8: 
77–82.
 25. Fine JP, Gray RJ. A proportional hazards model for the subdistribu-
tion of a competing risk. J Am Stat Assoc. 1999;94:496–509. DOI: DOI: 
10.1080/01621 459.1999.10474144.
 26. Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S. 
Hazzard’s Geriatric Medicine and Gerontology. 6th ed. New York, NY: 
McGraw-Hill Medical; 2009.
 27. Dai X, Hummel SL, Salazar JB, Taffet GE, Zieman S, Schwartz JB. 
Cardiovascular physiology in the older adults. J Geriatr Cardiol. 
2015;12:196–201.
 28. Herrera MD, Mingorance C, Rodriguez-Rodriguez R, Alvarez de 
Sotomayor M. Endothelial dysfunction and aging: an update. Ageing 
Res Rev. 2010;9:142–152. DOI: 10.1016/j.arr.2009.07.002.
 29. Nadruz W Jr, Kitzman D, Windham BG, Kucharska-Newton A, Butler 
K, Palta P, Griswold ME, Wagenknecht LE, Heiss G, Solomon SD, et 
al. Cardiovascular dysfunction and frailty among older adults in the 
community: the ARIC study. J Gerontol A Biol Sci Med Sci. 2017;72: 
958–964.
 30. Villani ER, Tummolo AM, Palmer K, Gravina EM, Vetrano DL, 
Bernabei R, Onder G, Acampora N. Frailty and atrial fibrillation: a 
systematic review. Eur J Intern Med. 2018;56:33–38. DOI: 10.1016/j.
ejim.2018.04.018.
 31. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on 
the utilisation of antithrombotic therapy in older patients with atrial fibril-
lation. Age Ageing. 2009;38:156–162. DOI: 10.1093/agein g/afn293.
 32. Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of 
atrial fibrillation for older people with frailty: a systematic review and 
meta-analysis. Age Ageing. 2019;48:196–203. DOI: 10.1093/agein g/
afy180.
 33. Oqab Z, Pournazari P, Sheldon RS. What is the impact of frailty on pre-
scription of anticoagulation in elderly patients with atrial fibrillation? A 
systematic review and meta-analysis. J Atr Fibrillation. 2018;10:1870. 
DOI: 10.4022/jafib.1870.
 34. McManus DD, Kiefe C, Lessard D, Waring ME, Parish D, Awad HH, 
Marino F, Helm R, Sogade F, Goldberg R, et al. Geriatric conditions 
and prescription of vitamin K antagonists vs. direct oral anticoagulants 
among older patients with atrial fibrillation: SAGE-AF. Front Cardiovasc 
















 http://ahajournals.org by on February 16, 2021
Table S1. Study Sample Characteristics of the Framingham Heart Study Offspring Cohort 
Participants Included in the Analysis of Rockwood Frailty Group at Exam 8 and Incident 











Age, years  69.6 (6.8) 67.7 (6.0) 70.0 (6.8) 72.8 (7.3) 
Female  1,125 (56.3) 455 (52.9) 429 (57.5) 241 (61.2) 
Current smoker 149 (7.5) 55 (6.4) 54 (7.2) 40 (10.2) 
Diabetes 292 (14.9) 37 (4.3) 145 (19.8) 110 (29.5) 
Height, inches 65.4 (3.8) 65.9 (3.9) 65.2 (3.7) 64.6 (3.5) 
Weight, pounds 171 (38) 165 (33) 174 (40) 180 (43) 
Systolic BP, mm Hg 131 (17) 129 (17) 132 (16) 131 (18) 
Diastolic BP, mm Hg 73 (10) 74 (9) 73 (10) 69 (11) 
Antihypertensive treatment 1,078 (54.0) 351 (40.9) 446 (59.8) 281 (71.7) 
PR interval, msec 17.0 (2.9) 16.7 (2.7) 17.0 (2.9) 17.4 (3.1) 
Heart Murmur/VHD  63 (3.3) 19 (2.3) 22 (3.1) 22 (6.2) 
Left ventricular hypertrophy 14 (0.72) 8 (0.94) 3 (0.42) 3 (0.80) 
Prevalent heart failure 25 (1.3) 0 (0.0) 10 (1.3) 15 (3.8) 
Prevalent coronary  
heart disease 
207 (10.4) 39 (4.5) 88 (11.8) 80 (20.3) 
Fried Frailty score 0.76 (0.95) 0.31 (0.53) 0.77 (0.79) 1.73 (1.18) 
Rockwood Frailty Index score 0.14 (0.11) 0.056 (0.028) 0.15 (0.031) 0.32 (0.089) 
Usual walking speed, m/s 1.17 (0.26) 1.27 (0.23) 1.17 (0.24) 0.96 (0.25) 
All values represent either mean (SD) or n (%). Participants with prevalent AF at exam 8 
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Table S2. Study Sample Characteristics of the Framingham Heart Study Offspring Cohort 
Participants Included in the Analysis of Prevalent Atrial Fibrillation at Exam 8 and New-
Onset Frailty, as defined using Rockwood criteria, at Exam 9 (N=1,343). 







Age, years  68.1 (6.2) 68.0 (6.1) 70.3 (6.4) 
Female  702 (53.0) 687 (54.4) 15 (24.2) 
Current smoker 80 (6.0) 78 (6.2) 2 (3.2) 
Diabetes 139 (10.6) 131 (10.4) 8 (13.1) 
Height, inches 65.7 (3.9) 65.6 (3.8) 67.5 (3.9) 
Weight, pounds 171 (37) 170 (36) 193 (39) 
Systolic blood pressure, mm Hg 129 (17) 129 (17) 127 (17) 
Diastolic blood pressure, mm Hg 74 (9) 74 (9) 73 (9) 
Antihypertensive treatment 631 (47.7) 595 (47.2) 36 (58.1) 
PR interval, msec 16.8 (2.8) 16.8 (2.7) 18.8 (3.2) 
Heart murmur 34 (2.6) 33 (2.6) 1 (1.7) 
Left ventricular hypertrophy 9 (0.68) 8 (0.65) 1 (1.7) 
Prevalent heart failure 10 (0.76) 5 (0.40) 5 (8.1) 
Prevalent coronary heart disease 114 (8.6) 95 (7.5) 19 (30.7) 
Fried Frailty score 0.48 (0.67) 0.48 (0.68) 0.45 (0.62) 
Rockwood Frailty Index score 0.095 (0.053) 0.094 (0.053) 0.11 (0.048) 
Usual walking speed, m/s 1.24 (0.24) 1.24 (0.24) 1.18 (0.24) 
All values represent either mean (SD) or n (%). Participants with prevalent frailty using 
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Table S3. Summary statistics comparing those with missing or incomplete frailty scores to 
those with complete frailty scores among FHS Offspring cohort participants aged ≥60 years 
who attended examination cycle 8 (n=2,328). 
Variable 
Missing Fried Frailty  
Score* at Exam 8 
Missing Rockwood Frailty  













Age, years 70.1 (7.0) 80.0 (7.9) <0.0001 70.0 (7.0) 77.3 (8.4) <0.0001 
Systolic blood pressure, mm Hg 131 (17) 134 (23) 0.34 131 (17) 134 (20) 0.09 
Diastolic blood pressure, mm Hg 72 (10) 69 (10) 0.01 72 (10) 70 (10) 0.02 
Female sex 1237 (54.6) 44 (69.8) 0.02 1216 (54.9) 65 (58.0) 0.51 
Current smoker 163 (7.2) 4 (6.4) 0.99 158 (7.1) 9 (8.0) 0.72 
Hypertension treatment 1254 (55.4) 45 (71.4) 0.01 1231 (55.6) 68 (60.7) 0.29 
History of CHD 293 (12.9) 16 (25.4) 0.004 291 (13.1) 18 (16.1) 0.37 
History of CHF 71 (3.1) 7 (11.1) 0.004 68 (3.1) 10 (8.9) 0.004 
History of AF 206 (9.1) 11 (17.5) 0.02 200 (9.0) 17 (15.2) 0.03 
Follow-up status*** 
      Censored 
      Incident AF case 





















Table values are mean (SD) or n (%) unless otherwise indicated.   
*Missingness was defined as ≥2 components for the Fried frailty score or ≥5 components for the 
Rockwood frailty score. 
**P-value calculated using either a t-test, Chi-square test, or Fisher’s Exact test, as appropriate. 
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Table S4. Hazard ratios (HR) and 95% confidence intervals (CI) for the association between frailty status at exam 8 and 










# AF events/ # 
participants 
HR (95% CI) 
P-
value 
# AF events/ # 
participants 
HR (95% CI) P-value 
Age/sex Robust 128/1,018 Ref --- 100/860 Ref --- 
Pre-frail 155/903 1.25 (0.98-1.59) 0.07 124/746 1.33 (1.02-1.74) 0.04 
Frail 23/132 1.26 (0.79-2.00) 0.33 74/394 1.64 (1.19-2.25) 0.002 
Age/sex/smoking Robust 128/1,018 Ref --- 100/860 Ref --- 
Pre-frail 155/903 1.24 (0.98-1.58) 0.08 124/746 1.33 (1.01-1.73) 0.04 
Frail 23/132 1.24 (0.78-1.97) 0.38 74/394 1.63 (1.19-2.24) 0.003 
Multivariable * Robust 123/958 Ref --- 96/819 Ref --- 
Pre-frail 139/822 1.10 (0.85-1.42) 0.49 117/690 1.18 (0.88-1.58) 0.27 
Frail 15/106 0.81 (0.46-1.43) 0.54 61/338 1.16 (0.79-1.70) 0.44 
*Models are adjusted for age, sex, current smoking, height, weight, systolic and diastolic blood pressure, antihypertensive treatment, 
current smoking, diabetes, PR interval, left ventricular hypertrophy, heart murmur, prevalent coronary heart disease, and prevalent 
heart failure. 
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